Physician profile
Leonid Chernov
NPI 1902801145
$10,214.79
in general payments reported to CMS, 2019-2025
32 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,495 · 2020: $1,210 · 2021: $1,790 · 2022: $1,679 · 2023: $1,410 · 2024: $680 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,020 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,020.03 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,996.88 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $1,234.59 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $883.24 | 2019-2025 | Verquvo, Steglatro, Capvaxive |
| Amgen INC. | $838.12 | 2019-2024 | Repatha, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $754.17 | 2019-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $631.88 | 2019-2025 | Jardiance |
| Pfizer INC. | $548.12 | 2019-2025 | |
| Amarin Pharma, INC. | $458.23 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $415.91 | 2021-2025 | |
| Abbvie INC. | $377.11 | 2019-2023 | Viberzi, Linzess |
| Regeneron Healthcare Solutions, INC. | $255.65 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $226.77 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $206.33 | 2019-2020 | |
| Glaxosmithkline, LLC. | $164.40 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $142.91 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $139.60 | 2020-2022 | |
| Scpharmaceuticals INC. | $130.65 | 2023-2025 | |
| Esperion Therapeutics, INC. | $119.76 | 2025 | Nexletol |
| Vifor Pharma, INC. | $113.90 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.58 | 2019-2022 | |
| Novo Nordisk INC | $92.10 | 2019-2025 | Ozempic, Wegovy |
| Corcept Therapeutics | $84.34 | 2025 | Korlym |
| Philips North America LLC | $54.56 | 2025 | Ecc Solutions |
| Gilead Sciences, INC. | $50.96 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $42.99 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $40.05 | 2023-2025 | Amvuttra |
| Arbor Pharmaceuticals, INC. | $32.42 | 2019 | |
| Sanofi Pasteur INC. | $18.57 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $17.90 | 2023 | Inpefa |
| Takeda Pharmaceuticals U.S.A., INC. | $17.65 | 2021 | |
| Allergan, INC. | $16.64 | 2019 | |
| Heartflow, INC. | $13.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonid Chernov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.